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Rescuing artemisinin combination therapy in Africa 
Considerable eﬀ ort has been made to meet the 
challenges posed by decreased eﬀ ectiveness of the 
antimalarial artemisinin and its key partner drugs 
against Plasmodium falciparum in Cambodia and 
neighbouring countries.1,2 Despite the threat of 
resistance, malaria endemicity has actually been falling 
over the past decade in the Greater Mekong Subregion.3 
But what if such phenomena began to unfold in 
Africa, in those countries where the daily incidence 
of symptomatic malaria cases can equal the annual 
burden in some Asian countries? Hypolite Mavoko 
and colleagues report in The Lancet Global Health a 
study4 designed to compare current rescue treatment 
options for P falciparum malaria in Africa, should front-
line therapies fail. The authors set out to formally test 
whether, in the event of recurrence of malaria symptoms 
in children receiving the recommended artemisinin-
based combination therapy (ACT), retreatment with 
that same regimen was inferior to either an alternative 
ACT, or the current WHO recommendation for rescue 
treatment, oral quinine plus an antibiotic (in this study, 
quinine plus clindamycin, QnC). 
The team recruited children aged 12–59 months 
who presented with laboratory-conﬁ rmed P falciparum 
malaria to either of two clinics, in Kinshasa, DR Congo or 
Mbarara, Uganda. Both sites serve populations exposed 
to intense malaria transmission. First-line ACT diﬀ ers 
between these countries, with artesunate-amodiaquine 
(ASAQ) used in DR Congo, and artemether-lumefantrine 
(AL) in Uganda. In an unusual design, passive follow-up 
identiﬁ ed treated participants with recurrent symptoms 
within 42 days; on second presentation with conﬁ rmed 
falciparum malaria, these children were then randomly 
assigned to one of three second treatments. The ﬁ rst 
group was retreated with the same ACT as used for 
the original malaria episode (retreatment ACT group), 
the second group with the alternative ACT (AL in DR 
Congo and ASAQ in Uganda) and the third group with 
the WHO recommendation, QnC. All treatment was fully 
observed, and 571 randomised children were actively 
followed up for 28 days. 
The primary outcome was the proportion of children 
with adequate clinical and parasitological response 
(ACPR) at day 28 after treatment, after PCR adjustment. 
The desired outcome was reached by most children 
in all three groups: ACPR was achieved by 91·4% of 
patients in the retreatment ACT group, by 91·3% in 
the alternative ACT group, and by 89·5% in the QnC 
group. This is good news, on the face of it, for national 
malaria control programmes in Africa. These ﬁ gures 
suggest there is no need to pick out recurrent malaria 
for special treatment, as the ﬁ rst-line ACT appears to 
be no less eﬀ ective against these malaria cases than 
against primary infections. Furthermore, some eﬀ ort 
was made in the study to capture any evidence that 
retreatment might lead to an excess of adverse events 
among the participants. As might have been expected, 
adverse events were signiﬁ cantly more common among 
children receiving the same ACT twice, but none of the 
reported adverse events were considered serious—the 
researchers conclude that, when combined with results 
of other studies, the weight of evidence suggests re-
treatment with the ﬁ rst-line ACT is safe. 
Two caveats are worth considering here. First, as the 
authors correctly emphasise, retreatment with the 
front-line regimen might enhance development of 
genetic resistance in P falciparum populations. Current 
evidence from Africa suggests that small diﬀ erences in 
susceptibility to ACT can be measured in vivo and in vitro; 
these are probably mediated by complex multi-locus 
genotypes, and are certainly not associated with variants 
of the pfk 13 locus as seen in the Mekong.5–9 Failure to 
provide an alternative regimen as rescue treatment for 
recurrent cases might lead to unidirectional selection 
on parasite genomes. Eﬃ  cacy on the front-line therapy 
should therefore be regularly monitored, with parasite 
genotyping at sentinel sites in each country. 
The second caveat relates to the use of PCR-corrected 
data to deﬁ ne the primary outcome. This well established 
approach ampliﬁ es highly polymorphic sequences in 
certain parasite genes. Fractionation of these amplicons 
on agarose gels generates patterns that are compared 
between the recurrence, and the day 0 (pre-treatment) 
parasite population. So-called true treatment failures are 
expected to maintain a pattern at recurrence resembling 
that at day 0. Dissimilar patterns are considered to have 
newly arisen, emerging from the liver after circulating 
drug concentrations have dropped, and thus bearing a 
genetic signature that diﬀ ers from the original infection. 
Unfortunately, this method is notoriously unreliable 
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because of misclassiﬁ cation errors, particularly in 
Africa.7,10 Crude ACPR, without PCR correction, presents 
a bleaker picture of drug eﬃ  cacy. In this study, crude 
ACPR estimates were 60·5% (retreatment ACT), 56·2% 
(alternate ACT), and 70·8% (QnC). This ﬁ nding clearly 
shows a major problem: our front-line antimalarial 
regimens in Africa leave a substantial proportion of 
treated individuals with persistent parasitaemia, and 
thus do not prevent onward transmission to mosquitoes 
of drug-exposed parasites. This is of major concern, and 
suggests that potential strategies for improving sterile 
parasite clearance need consideration, such as longer 
courses of artemisinin combination therapy, and use of 
two or more partner drugs. 
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